| Keryx Biopharmaceuticals, Inc. (KERX) Price Down, Not Company's Potential - International Business Times |
|
|
International Business Times Regarding therapies for end-stage renal disease (ESRD), a more than billion-dollar market controlled by Genzyme (NASDAQ:GENZ) with Renagel and Renvela, |